GlassScriptPhysician profile
Faiq Akhter
NPI 1801896303
$8,519.70
in general payments reported to CMS, 2019-2025
36 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $1,292 · 2021: $250 · 2022: $2,220 · 2023: $928 · 2024: $1,879 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,702 · Food and Beverage: $1,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,702.13 |
| Food and Beverage | $1,404.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,949.02 | 2019-2020 | |
| Penumbra, INC. | $1,769.23 | 2022 | |
| Boston Scientific Corporation | $1,432.63 | 2022-2025 | Watchman Access System, Cds - Mct/Cem Monitoring, Watchman Flx |
| Abbott Laboratories | $748.00 | 2023-2024 | Mitraclip |
| Medtronic, INC. | $311.84 | 2021-2024 | Corevalve Evolut R |
| Inari Medical, INC. | $306.15 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $290.34 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $218.11 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $215.85 | 2019-2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $133.23 | 2019 | |
| Amgen INC. | $128.40 | 2019-2022 | |
| Abiomed | $122.64 | 2022-2025 | Impella |
| Angiodynamics, INC. | $110.45 | 2021-2023 | Auryon Laser System 100-120 Vac |
| Lundbeck LLC | $77.57 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $76.44 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $74.25 | 2019 | |
| Pfizer INC. | $69.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.23 | 2019-2022 | |
| Shockwave Medical, INC | $57.12 | 2025 | |
| Livanova USA, INC. | $49.01 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $40.22 | 2020-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $37.88 | 2019 | |
| Terumo Medical Corporation | $31.63 | 2021 | |
| Amarin Pharma, INC. | $29.79 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $29.65 | 2025 | Assure Wcd |
| Ge Healthcare | $21.38 | 2021 | |
| Merck Sharp & Dohme LLC | $19.53 | 2022 | |
| Cvrx, INC. | $19.44 | 2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $16.27 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2022 | |
| Astellas Pharma US INC | $13.52 | 2019 | |
| Cardiovascular Systems INC. | $13.10 | 2021 | |
| Elutia, INC. | $12.40 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiq Akhter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.